147 related articles for article (PubMed ID: 3487650)
1. A prospective evaluation of 118 patients with the fibromyalgia syndrome: prevalence of Raynaud's phenomenon, sicca symptoms, ANA, low complement, and Ig deposition at the dermal-epidermal junction.
Dinerman H; Goldenberg DL; Felson DT
J Rheumatol; 1986 Apr; 13(2):368-73. PubMed ID: 3487650
[TBL] [Abstract][Full Text] [Related]
2. Antinuclear antibodies and connective tissue disease features in fibromyalgia syndrome: a controlled study.
Yunus MB; Hussey FX; Aldag JC
J Rheumatol; 1993 Sep; 20(9):1557-60. PubMed ID: 8164214
[TBL] [Abstract][Full Text] [Related]
3. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
Rychlik-Golema W; Mastej K; Adamiec R
Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
[TBL] [Abstract][Full Text] [Related]
4. In vivo anti-nuclear antibodies in epithelial biopsies in SLE and other connective tissue diseases.
Wells JV; Webb J; Van Deventer M; Fry B; Pollard KM; Raftos J; Monk W; Nelson DS
Clin Exp Immunol; 1979 Dec; 38(3):424-35. PubMed ID: 394890
[TBL] [Abstract][Full Text] [Related]
5. The prevalence and significance of positive antinuclear antibodies in patients with fibromyalgia syndrome: 2-4 years' follow-up.
Al-Allaf AW; Ottewell L; Pullar T
Clin Rheumatol; 2002 Nov; 21(6):472-7. PubMed ID: 12447630
[TBL] [Abstract][Full Text] [Related]
6. Increased prevalence of sicca complex and fibromyalgia in patients with irritable bowel syndrome.
Barton A; Pal B; Whorwell PJ; Marshall D
Am J Gastroenterol; 1999 Jul; 94(7):1898-901. PubMed ID: 10406256
[TBL] [Abstract][Full Text] [Related]
7. A controlled and blinded study of immunoreactant deposition at the dermal-epidermal junction of patients with primary fibrositis syndrome.
Caro XJ; Wolfe F; Johnston WH; Smith AL
J Rheumatol; 1986 Dec; 13(6):1086-92. PubMed ID: 3550073
[TBL] [Abstract][Full Text] [Related]
8. Isolated Raynaud's phenomenon--a benign disorder.
Sheiner NM; Small P
Ann Allergy; 1987 Feb; 58(2):114-7. PubMed ID: 3492946
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic factors in Raynaud's phenomenon: usefulness of antinuclear antibodies and of periungual capillaroscopy].
Passiu G; Sebastiani GD; Galeazzi M; Tuveri MA; Nicosia PM; Boirivant R
Medicina (Firenze); 1990; 10(4):405-7. PubMed ID: 2099984
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of vascular injury with proinflammatory cytokines, thrombomodulin and fibronectin in patients with primary fibromyalgia.
Pay S; Calgüneri M; Calişkaner Z; Dinç A; Apraş S; Ertenli I; Kiraz S; Cobankara V
Nagoya J Med Sci; 2000 Nov; 63(3-4):115-22. PubMed ID: 11201985
[TBL] [Abstract][Full Text] [Related]
11. Epidermal nuclear immunoglobulin deposition in connective tissue diseases.
Rodrigues CJ; de Oliveira RM; Taniwaki NN; Bueno C; Marchiori P; Cossermelli W
Rev Hosp Clin Fac Med Sao Paulo; 1990; 45(4):154-7. PubMed ID: 2135825
[TBL] [Abstract][Full Text] [Related]
12. [Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen diseases].
Kumagai S; Morinobu A; Ozaki S; Nakao K; Ishida H
Ryumachi; 1998 Jun; 38(3):504-10. PubMed ID: 9721558
[TBL] [Abstract][Full Text] [Related]
13. Need to expand microvascular investigation of patients with Raynaud's phenomenon of different etiology: clinical patterns of 106 consecutive patients.
Arpaia G; Cimminiello C; Bellone M; Aloisio M; Rossi F; Bonfardeci G
Int Angiol; 1994 Mar; 13(1):15-8. PubMed ID: 8077792
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological evaluation of in vivo epidermal nuclear fluorescence.
Sousa JX; Miyamoto D; Zimbres JM; Costa DV; Aoki V
Clin Exp Dermatol; 2009 Apr; 34(3):314-8. PubMed ID: 19040522
[TBL] [Abstract][Full Text] [Related]
15. Raynaud's phenomenon in systemic lupus erythematosus.
Lavras Costallat LT; Valente Coimbra AM
Rev Rhum Engl Ed; 1995 May; 62(5):349-53. PubMed ID: 7655867
[TBL] [Abstract][Full Text] [Related]
16. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.
Kallenberg CG; Pastoor GW; Wouda AA; The TH
Ann Rheum Dis; 1982 Aug; 41(4):382-7. PubMed ID: 7051989
[TBL] [Abstract][Full Text] [Related]
17. Systemic autoimmune disease and Raynaud's phenomenon: a common, immunologically mediated, vascular basis?
Kallenberg CG; Wouda AA; The TH
Neth J Med; 1984; 27(9):322-6. PubMed ID: 6334812
[No Abstract] [Full Text] [Related]
18. Serological arguments for classifying Raynaud's phenomenon as idiopathic.
Gentric A; Blaschek MA; Le Noach JF; Johanet C; Jouquan J; Lamour A; Abuaf N; Pennec YL; Youinou P
J Rheumatol; 1990 Sep; 17(9):1177-81. PubMed ID: 2290158
[TBL] [Abstract][Full Text] [Related]
19. Severe Raynaud's phenomenon in a patient with antinuclear antibody-negative systemic lupus erythematosus.
Maxwell CJ; Potter E; Townsend J
J Natl Med Assoc; 1988 May; 80(5):594-5. PubMed ID: 3262169
[TBL] [Abstract][Full Text] [Related]
20. Clinical and serological heterogeneity in patients with anticentromere antibodies.
Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
